Mounjaro®
Starting from £179.99/mo
Start journey Learn moreOzempic is a semaglutide injection licensed in the UK for type 2 diabetes, not for weight loss. Many people search for "weight loss injections Ozempic" after hearing the brand name, but the UK medicines licensed specifically for weight management are Wegovy (also semaglutide) and Mounjaro (tirzepatide). All three are prescription-only medicines that need a clinical assessment first. So if losing weight is your goal, the honest starting point is knowing which product the rules point you toward, and why the label matters more than the headline.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The name stuck. Ozempic became shorthand for the whole category after it appeared widely online, so a lot of people arrive searching for Ozempic weight loss injections in the UK when what they actually want is a treatment they can be prescribed for weight. That's a fair mix-up, and worth untangling before you go any further.
Here's the distinction. Ozempic contains semaglutide and is licensed by the MHRA for type 2 diabetes. Wegovy also contains semaglutide, at doses set for weight management, and that's the version licensed for weight loss. Same active ingredient, different licence, different pen. It isn't a marketing quirk. A medicine's licence tells your prescriber what it has been assessed and authorised to do, and the NHS medicines guidance on semaglutide reflects that split.
So no reputable UK pharmacy will supply Ozempic as a weight-loss injection. If you meet the criteria, the licensed semaglutide route for weight is Wegovy. Understanding that one point saves a lot of confusion later, especially when you're comparing prices or reading claims online.
Once you know Ozempic is off the table for weight, the real decision narrows to two medicines. Both are once-weekly injections. Both need a prescriber's yes.
Wegovy is semaglutide dosed for weight management, working on the GLP-1 pathway that influences appetite and how full you feel. Mounjaro is tirzepatide, which acts on two gut-hormone receptors rather than one. If you want the mechanics rather than the brand names, our explainer on how these semaglutide injections work for weight loss walks through the appetite and gastric-emptying effects in plain terms.
People also want to know how effective each one is. In clinical trials, semaglutide 2.4mg (the STEP 1 study) produced an average weight reduction of around 15% over 68 weeks, while tirzepatide reached roughly 20% at its higher doses in the SURMOUNT programme. Those are trial averages, not promises, and your result depends on many things. If you'd rather stay with the semaglutide family, our page on semaglutide weight-loss injections covers that side in more depth.
Neither is "better" in the abstract. Which suits you is a clinical judgement made with a prescriber, weighing your history, other medicines and how your body responds.
Licensing sets the outer boundary of who can be considered. For weight management, both Wegovy and Mounjaro are licensed for adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. Lower thresholds can apply for some ethnic backgrounds under UK guidance.
BMI on its own never decides it, though. A prescriber looks at the whole picture: your medical history, current medicines, and whether an injection is a sensible fit for you specifically. That's why the licence is a starting gate, not a guarantee.
These treatments are also meant to sit alongside a reduced-calorie diet and more physical activity, not replace them. If you want to check the numbers side of eligibility first, the NHS BMI calculator is a straightforward place to start before any consultation. You can also read more about the treatment options on our weight-loss overview.
One group where the answer is clear either way: these medicines are not licensed for under-18s, and they aren't recommended in pregnancy, while breastfeeding, or if you're trying to conceive. Those are firm lines, not case-by-case ones.
Practicality matters more than people expect. Both Wegovy and Mounjaro are given once a week, on the same day each week, with the day you choose being yours to set with your prescriber's guidance. You can move it if you need to, within the rules in your Patient Information Leaflet.
The injection goes into the fat just under the skin, usually the abdomen, thigh or upper arm, and you rotate the site each time. If you're squeamish about that part, you're in good company; it's one of the questions our prescribers hear most weeks. Our guides on where to inject Wegovy and how to use the Wegovy pen take the mystery out of it.
Storage is the other practical piece. These pens are kept refrigerated, with a limited room-temperature window that your leaflet specifies exactly, which matters if you travel. Our note on whether Wegovy needs refrigerating covers the day-to-day of keeping a pen in the fridge door and taking it away with you.
A quick timing thought worth planning around: if you order at the start of a month or just after payday, factor in that treatment is re-reviewed clinically before every repeat, so it isn't an automatic subscription that fires regardless. That's deliberate.
The most common effects of these injections are gastrointestinal. Nausea, some stomach upset, occasional constipation or diarrhoea, and a bit of tiredness or headache tend to show up most after starting or after a dose goes up, and for many people they settle within a couple of weeks. Everyone's different, and your prescriber can talk through what to expect.
There's a more serious signal to know. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 medicines. The thing to act on is severe, persistent stomach pain that may spread through to your back, with or without vomiting: that warrants urgent medical help. Our fuller page on the side effects of these weight-loss injections goes through the picture calmly and in detail.
If you ever have a side effect you're worried about, you can also report it through the MHRA Yellow Card scheme, which is how the UK keeps track of medicine safety in the real world. Reporting doesn't replace getting medical advice; it sits alongside it.
None of this is meant to alarm you. Most people tolerate treatment well. It's simply the honest trade-off any prescription medicine carries, and knowing the warning signs is part of using one sensibly.
On the NHS, weight-loss injections are rationed through strict, phased criteria. Tirzepatide is being introduced gradually: as things stand the earliest cohorts need a high BMI plus several qualifying conditions, and some GP practices can prescribe under the new arrangements while others in the same area may not. Wegovy on the NHS runs through specialist weight-management services under NICE guidance, where waiting lists are commonly long.
You can read the official phasing in the NICE recommendation for tirzepatide (TA1026), which sets out who qualifies and when. It's genuinely restrictive by design, so plenty of people who'd like treatment don't currently meet the bar or don't want to wait months.
A regulated private pharmacy is the alternative for those people. It isn't the NHS and doesn't pretend to be; it's a legitimate, prescriber-led route for adults who meet the licensed criteria. The safety expectations are the same either way: an assessment, a genuine supply chain, and proper aftercare.
One firm caution wherever you buy. Sellers offering these medicines without a prescription, or through social media, or at prices far below the market, are a red flag. The MHRA has seized large volumes of fake weight-loss pens, some of which contained the wrong drug entirely. Always confirm a pharmacy on the GPhC register before you buy.
We should be plain: we don't dispense Ozempic for weight loss, because it isn't licensed for it. What we do offer, subject to clinical suitability, are the licensed weight-management injections, Wegovy and Mounjaro, through our GPhC-registered UK pharmacy.
The process is straightforward. You complete a free online consultation, and a named prescriber reads your answers the same day, not an algorithm sorting a queue. We verify your identity with photo ID and confirm your weight on video, in line with GPhC guidance, and notify your GP where appropriate. If treatment is approved and you've ordered before 12pm on a working day, it's dispatched the same day and delivered free the next working day by DPD, in plain packaging.
Everything sits under one transparent price: the consultation, the prescription, the treatment, delivery and aftercare seven days a week. There's no subscription and no auto-renewal; every repeat is clinically re-reviewed. You can read about who we are or meet our clinical team if you'd like to know who's behind that.
When you're ready, the sensible next step isn't buying anything; it's finding out whether a licensed injection is right for you. Check your eligibility with a free consultation and let a prescriber take it from there.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.